Non Small Cell Lung Cancer Stage Iii clinical trials

Explore recruiting non small cell lung cancer stage iii clinical trials.

Recruiting non small cell lung cancer stage iii studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Small Cell Lung Cancer Stage Iii trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I clinical trial of TG4050 combined with nivolumab in patients with Non-Small Cell Lung Cancer.

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) (PACIFIC2)

Poland, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I clinical trial evaluating TG4070 in patients with non-small cell lung cancer

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)

Poland, Spain, Portugal, Belgium, France, Greece +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequential hyPOfractionated chemoRADiotherapy in unfit or elderly patients with unresectable stage III non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Small Cell Lung Cancer Stage Iii trials by city

Non Small Cell Lung Cancer Stage Iii in Toronto Non Small Cell Lung Cancer Stage Iii in Vancouver Non Small Cell Lung Cancer Stage Iii in Montreal Non Small Cell Lung Cancer Stage Iii in Calgary Non Small Cell Lung Cancer Stage Iii in Edmonton Non Small Cell Lung Cancer Stage Iii in Ottawa Non Small Cell Lung Cancer Stage Iii in Winnipeg Non Small Cell Lung Cancer Stage Iii in Quebec City Non Small Cell Lung Cancer Stage Iii in Hamilton Non Small Cell Lung Cancer Stage Iii in Kitchener Non Small Cell Lung Cancer Stage Iii in London Non Small Cell Lung Cancer Stage Iii in Halifax Non Small Cell Lung Cancer Stage Iii in New York Non Small Cell Lung Cancer Stage Iii in Los Angeles Non Small Cell Lung Cancer Stage Iii in Chicago Non Small Cell Lung Cancer Stage Iii in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease